
|Articles|August 1, 2003
Multiple-dose regimen safe for neovascular AMD
Author(s)Cheryl Guttman
Fort Lauderdale, FL-In a phase I, multicenter, randomized trial, the anti-VEGF antibody fragment rhuFab V2 was shown to be safe and well-tolerated in eyes with neovascular age-related macular degeneration (AMD), according to Philip J. Rosenfeld, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Redefining glaucoma care: Where innovation meets clinical insight
3
Beyond the surface: Tackling complex dry eye cases
4
Seborrheic dermatitis linked to multiple epithelial barrier diseases
5



















































.png)


